Andrea Ferrari1, Yueh-Yun Chi2, Gian Luca De Salvo3, Daniel Orbach4, Bernadette Brennan5, R Lor Randall6, M Beth McCarville7, Jennifer O Black8, Rita Alaggio9, Douglas S Hawkins10, Gianni Bisogno11, Sheri L Spunt12. 1. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. Electronic address: andrea.ferrari@istitutotumori.mi.it. 2. Department of Biostatistics, University of Florida, Gainesville, FL, USA. 3. Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy. 4. Department of Pediatric, Adolescent and Young Adult Oncology, Institut Curie, Paris, France. 5. Department of Pediatric Oncology, Royal Manchester Children's Hospital, Manchester, United Kingdom. 6. Pediatric Orthopaedics, Primary Children's Hospital, Salt Lake City, UT, USA. 7. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA. 8. Pediatric Pathology, Children's Hospital Colorado, Aurora, CO, USA. 9. Pathology Department, Padova University, Padova, Italy. 10. Hematology/Oncology, Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 11. Pediatric Hematology and Oncology Division, Padova University, Padova, Italy. 12. Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.
Abstract
BACKGROUND: Multimodal risk-adapted treatment is used in paediatric protocols for synovial sarcoma (SS). Retrospective analyses suggest that low-risk SS patients can be safely treated with surgery alone, but no prospective studies have confirmed the safety of this approach. This analysis pooled data from the two prospective clinical trials to assess outcomes in SS patients treated with a surgery-only approach and to identify predictors of treatment failure. METHODS: Patients with localised SS enrolled on the European paediatric Soft tissue sarcoma Study Group (EpSSG) NRSTS2005 and on the Children Oncology Group (COG) ARST0332 trials, treated with surgery alone were eligible for this analysis. Patients must have undergone initial complete resection with histologically free margins, with a grade 2 tumour of any size or a grade 3 tumour ≤5 cm. RESULTS: Sixty patients under 21 years of age were eligible for the analysis; 36 enrolled in the COG (from 2007 to 2012) and 24 in the EpSSG study (from 2005 to 2012). The 3-year event-free survival was 90% (median follow-up 5.2 years, range 1.9-9.1). All eight events were local tumour recurrence, whereas no metastatic recurrences were seen. All patients with recurrence were effectively salvaged, resulting in 100% overall survival. CONCLUSION: This joint prospective analysis showed that patients with adequately resected ≤5 cm SS, regardless of grade, can be safely treated with a surgery-only approach. Avoiding the use of adjuvant chemotherapy and radiotherapy in this low-risk patient population may decrease both short- and long-term morbidity and mortality.
BACKGROUND: Multimodal risk-adapted treatment is used in paediatric protocols for synovial sarcoma (SS). Retrospective analyses suggest that low-risk SS patients can be safely treated with surgery alone, but no prospective studies have confirmed the safety of this approach. This analysis pooled data from the two prospective clinical trials to assess outcomes in SS patients treated with a surgery-only approach and to identify predictors of treatment failure. METHODS:Patients with localised SS enrolled on the European paediatric Soft tissue sarcoma Study Group (EpSSG) NRSTS2005 and on the Children Oncology Group (COG) ARST0332 trials, treated with surgery alone were eligible for this analysis. Patients must have undergone initial complete resection with histologically free margins, with a grade 2 tumour of any size or a grade 3 tumour ≤5 cm. RESULTS: Sixty patients under 21 years of age were eligible for the analysis; 36 enrolled in the COG (from 2007 to 2012) and 24 in the EpSSG study (from 2005 to 2012). The 3-year event-free survival was 90% (median follow-up 5.2 years, range 1.9-9.1). All eight events were local tumour recurrence, whereas no metastatic recurrences were seen. All patients with recurrence were effectively salvaged, resulting in 100% overall survival. CONCLUSION: This joint prospective analysis showed that patients with adequately resected ≤5 cm SS, regardless of grade, can be safely treated with a surgery-only approach. Avoiding the use of adjuvant chemotherapy and radiotherapy in this low-risk patient population may decrease both short- and long-term morbidity and mortality.
Authors: Ines B Brecht; Andrea Ferrari; Christoph Int-Veen; Andreas Schuck; Adrian C Mattke; Michela Casanova; Gianni Bisogno; Modesto Carli; Ewa Koscielniak; Joern Treuner Journal: Pediatr Blood Cancer Date: 2006-01 Impact factor: 3.167
Authors: Andrea Ferrari; Gian Luca De Salvo; Odile Oberlin; Michela Casanova; Angela De Paoli; Annie Rey; Véronique Minard; Daniel Orbach; Modesto Carli; Bernadette Brennan; Max M Vannoesel; Carlo Morosi; Michael C Stevens; Gianni Bisogno Journal: Eur J Cancer Date: 2012-02-08 Impact factor: 9.162
Authors: Andrea Ferrari; Gianni Bisogno; Rita Alaggio; Giovanni Cecchetto; Paola Collini; Angelo Rosolen; Cristina Meazza; Paolo Indolfi; Alberto Garaventa; Luigi De Sio; Paolo D'Angelo; Paolo Tamaro; Michela Casanova; Modesto Carli Journal: Eur J Cancer Date: 2008-04-25 Impact factor: 9.162
Authors: A Ferrari; G L De Salvo; B Brennan; M M van Noesel; A De Paoli; M Casanova; N Francotte; A Kelsey; R Alaggio; O Oberlin; M Carli; M Ben-Arush; C Bergeron; J H M Merks; M Jenney; M C Stevens; G Bisogno; D Orbach Journal: Ann Oncol Date: 2014-12-08 Impact factor: 32.976
Authors: Sheri L Spunt; Nadine Francotte; Gian Luca De Salvo; Yueh-Yun Chi; Ilaria Zanetti; Andrea Hayes-Jordan; Simon C Kao; Daniel Orbach; Bernadette Brennan; Aaron R Weiss; Max M van Noesel; Lynn Million; Rita Alaggio; David M Parham; Anna Kelsey; R Lor Randall; M Beth McCarville; Gianni Bisogno; Douglas S Hawkins; Andrea Ferrari Journal: Eur J Cancer Date: 2019-04-05 Impact factor: 9.162
Authors: Rajkumar Venkatramani; Wei Xue; R Lor Randall; Suzanne Wolden; James Anderson; Dolores Lopez-Terrada; Jennifer Black; Simon C Kao; Barry Shulkin; Andrew Ostrenga; Alberto Pappo; Sheri L Spunt Journal: J Clin Oncol Date: 2021-10-08 Impact factor: 44.544
Authors: Fiorela N Hernandez Tejada; Alejandro Zamudio; Mario L Marques-Piubelli; Branko Cuglievan; Douglas Harrison Journal: Curr Oncol Rep Date: 2020-11-16 Impact factor: 5.075
Authors: James A Saltsman; Enrico Danzer; William J Hammond; Daniel Rhee; Simon Berhe; Julie Monteagudo; Anita P Price; Todd E Heaton; David R Jones; Michael P LaQuaglia Journal: Ann Surg Date: 2021-08-01 Impact factor: 13.787
Authors: Daniel Orbach; Véronique Mosseri; Daniel Pissaloux; Gaelle Pierron; Bernadette Brennan; Andrea Ferrari; Frederic Chibon; Gianni Bisogno; Gian Luca De Salvo; Camille Chakiba; Nadège Corradini; Véronique Minard-Colin; Anna Kelsey; Dominique Ranchère-Vince Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452
Authors: Cecilia Tetta; Antonio Giugliano; Laura Tonetti; Michele Rocca; Alessandra Longhi; Francesco Londero; Gianmarco Parise; Orlando Parise; Linda Renata Micali; Mark La Meir; Jos G Maessen; Sandro Gelsomino Journal: J Clin Med Date: 2020-04-23 Impact factor: 4.241
Authors: Sayed Abdulla Jami; Siam Al Mobarak; Shi Jiandang; Zhu Xi; M M Sohel Tanvir; Sonjoy Sutradhar Monilal Journal: Int J Health Sci (Qassim) Date: 2020 Nov-Dec